GlassScriptPhysician profile
Arti Subramanian
NPI 1194957431
$3,841.80
in general payments reported to CMS, 2019-2025
28 companies · $61.74 in 2025
The $61.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $242 · 2021: $781 · 2022: $841 · 2023: $762 · 2024: $53.48 · 2025: $61.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $464.88 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $425.13 | 2019-2023 | Breztri, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.12 | 2019-2023 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Abbvie INC. | $341.62 | 2019-2023 | Qulipta, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.96 | 2019-2023 | Xifaxan, Relistor |
| Novartis Pharmaceuticals Corporation | $242.13 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $217.39 | 2021-2023 | Rexulti |
| Glaxosmithkline, LLC. | $206.04 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $188.94 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $167.29 | 2019-2023 | Emgality |
| Janssen Pharmaceuticals, INC | $137.99 | 2019-2023 | Spravato |
| Merck Sharp & Dohme LLC | $122.95 | 2019-2022 | |
| Exact Sciences Corporation | $96.79 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $78.74 | 2021-2023 | Repatha, Otezla, Prolia |
| Amarin Pharma, INC. | $76.84 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $55.65 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.93 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $29.22 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.11 | 2022 | |
| Endogastric Solutions, INC | $22.78 | 2023 | Esophyx |
| Nevro Corp. | $22.50 | 2022 | |
| Mylan Specialty L.P. | $21.75 | 2023 | Yupelri |
| Ultragenyx Pharmaceutical INC. | $19.02 | 2019 | |
| Abbott Laboratories | $18.43 | 2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $14.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.60 | 2019 | |
| Alkermes, INC. | $13.48 | 2022 | |
| Grt US Holding, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arti Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.